CAMBRIDGE, Mass. (AP) _ Acceleron Pharma Inc. (XLRN) on Thursday reported a loss of $70.5 million in its third quarter.

The Cambridge, Massachusetts-based company said it had a loss of $1.16 per share. Losses, adjusted for stock option expense and non-recurring costs, were 95 cents per share.

The results beat Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 96 cents per share.

The clinical stage biotech developing protein therapeutics for cancer and rare diseases posted revenue of $34.2 million in the period, which missed Street forecasts. Six analysts surveyed by Zacks expected $36.6 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XLRN at https://www.zacks.com/ap/XLRN

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News